BioMed Research International

Review Article

Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis

Table 1

Study characteristics.


Study	Median age (year)		Gender (M/F)		Follow-up	Dose of RTX	Dose of DXM	Outcomes
Study	RTX+DXM	DXM	RTX+DXM	DXM	Follow-up	Dose of RTX	Dose of DXM	Outcomes

Chen Rongban et al. (2015)	46.0	48.0	33/27	32/28	4 weeks	100mg, weekly, 28 d	40mg, qd, 1~4d/cycle×2~4	CR, PR, OR on month 3; AE
Chen Shengmei et al. (2015)	46.7	46.9	13/22	15/20	4 weeks	100mg, weekly, 28 d	40mg, qd, 1~4d	CR, PR, OR on week 4; AE
Chen Yuji et al. (2015)	39.9	39.9	16/15	16/16	4 weeks	100mg, weekly, 28 d	40mg, qd, 1~4d	CR, PR, OR on week 4; AE
Cui Yunxia et al. (2015)	41.0	42.0	21/27	19/28	6 months	100mg, weekly, 28 d	12.5~25mg, bid~qid, 1~4d	CR, PR, OR on week 4; R; Treg cell count
Francesco Zaja et al. (2010)	49.0	47.0	22/27	19/33	6 months	375mg/m², weekly, 28d	40mg, qd, 1~4d	SR at month 12; R; AE; serious AE
Liu Kaige et al. (2012)	40.0	40.0	17/24	18/27	12 months	100mg, weekly, 28 d	40mg, qd, 1~4d	CR, PR, OR on week 4; SR at month 12; Treg cell count; AE
Meng Jingye et al. (2017)	38.0	35	18/10	20/8	4 weeks	100mg, weekly, 28 d	40mg, qd, 1~4d	CR, PR, OR on week 4; AE
Sif Gudbrandsdottir et al. (2013)	51.0	58.0	26/36	37/34	24 months	375mg/m², weekly, 28d	40mg, qd, 1~4d	SR at month 6 and 12; R; AE; serious AE
Yang Huijuan et al. (2010)	50.2	47.3	10/14	9/13	3 months	375mg/m² weekly, 28d	40mg, qd, 1~4d/cycle×4	CR, PR, OR on month 3; R; AE
Zhang Xiaojuan et al. (2015)	38.0		20/32		4 weeks	100mg, weekly, 28 d	40mg, qd, 1~4d	CR, PR, OR on month 3; SR at month 12; AE; serious AE
Zhenyu Li et al. (2011)	26.0	24.0	13/18	12/19	12 months	100mg, weekly, 28 d	40mg, qd, 1~4d	CR, PR, OR on week 4; SR at month 6; R; Treg cell count; AE

RTX: rituximab; DXM: dexamethasone; M: male; F: female; qid: once a day; bid: twice a day; qid four times a day; CR: complete response (platelet count⩾100×10⁹/L); PR: partial response (platelet count⩾30×10⁹/L); OR: overall response (OR=CR+PR); SR: sustained response (platelet count⩾50×10⁹/L at month 6); R: relapse (dropping in platelet count to⩽30×10⁹/L following a CR or PR); AE: adverse effect.